

# EXTRACELLULAR MATRIX TECHNOLOGY AS AN ADJUNCT TO PREVENT LIMB AMPUTATION IN THE DIABETIC FOOT ULCER (DFU) POPULATION

Donna Gilleece, Nurse Educator Vascular; Alicia Sutton, Diabetic Foot Nurse Specialist; Auckland District Health Board, Auckland, New Zealand

**~250,000**  
New Zealanders  
with T2DM

**19-34%**  
Affected by a DFU

**~600**  
Annual T2DM  
related  
amputations in NZ

Advanced ECM# shown to reduce the time close DFU by up to ~5 weeks!



**7**  
Complex DFU  
evaluated

**2-10 week**  
Treatment period

## Results and Conclusion

- All DFU responded well to treatment with advanced ECM
- Increased in granulation tissue, epithelialization and wound closure
- Advanced ECM was easy to use as part of SoC and may be considered for limb preservation in DFU

TABLE 1. PATIENT DEMOGRAPHICS AND OUTCOMES

Patient Age/Gender	Co-morbidities/ Challenges	Wound Age (Months)	Wound dimensions	Location	Weeks of treatment	Outcomes
70/M (Case #1)	T2DM HbA1c=65; PVD; HTN; ESRF; Exposed B/T Prior left foot amputation	6 weeks	8 x 6 cm	Left lateral calcaneous	8 weeks	Wound size reduction; granulation tissue increase, depth reduced and bone coverage; epithelialization Treatment halted due to undiagnosed osteomyelitis
45/F	T2DM HbA1c=126; Right foot2 lateral trauma resulting in cellulitis	2 weeks	6 x 3 cm	Forefoot - lateral	10 weeks	Wound size reduction; granulation tissue increase; epithelialization Closed at 10 weeks
46/F (Case #2)	T2DM HbA1c=57; ESRF; AF; HTN; Dyslipidaemia Peripheral neuropathy	1 day	5.5 x 2.5 cm	Forefoot - post TMA	10 weeks	Wound size reduction; granulation tissue increase Week 10 = 4 x 0.6 cm x 1cm
68/M	T2DM HbA1c=78; PVD; HTN; Exposed Joint	4 weeks	4 cm x 3 cm	Forefoot - MTP	2 weeks	Wound size reduction; granulation tissue increase; epithelialization Week 6 = 3 x 2.2 cm
42/F (Case #3)	T2DM HbA1c = 43; PVD; Osteomyelitis; HTN 3rd/4th toe amputation	2 days	8.5 x 0.5 cm (Plantar) 10 x 4.5 cm (Dorsum)	Forefoot	3 weeks	Wound size reduction (depth) and granular bed SGG (dorsal wound) placed at 19 days, with >75% SGG take at 7 days. Healed at week 15,
72/M	T2DM HbA1c = 67; ESRF; Peripheral Neuropathy; CABG; PVD; HTN	6 weeks	5 x 4 cm	Calcaneous	10 days	Wound size reduction; granulation tissue increase, depth reduced and bone coverage; epithelialization Treatment halted due to arterial occlusion
70/M (Case #4)	T2DM - HbA1c = 50; ESRF; PVD; Hypertension Myeloma; Prior TMA	1 week	5 x 3.5 cm	Forefoot - lateral	9 weeks	Wound reducing in size; granulation tissue; epithelialization Almost healed at 16 weeks

### Case 1:



### Case 2:



### Case 3:



### Case 4:



## REFERENCES AND DISCLOSURES

Product was provided by Aroa Biosurgery Limited (New Zealand); \*Endoform Natural Dermal Template (Aroa Biosurgery Limited, New Zealand).